E. Etaranda, A. Abad, and A. Carrato, Treatment recommendations for metastatic colorectal cancer, Clinical and Translational Oncology, vol.93, issue.4, pp.162-78, 2011.
DOI : 10.1002/bjs.5346

D. Cunningham, W. Atkin, and H. Lenz, Colorectal cancer, The Lancet, vol.375, issue.9719, pp.1030-1077, 2010.
DOI : 10.1016/S0140-6736(10)60353-4

N. Zdenkowski, S. Chen, and A. Van-der-westhuizen, Curative Strategies for Liver Metastases from Colorectal Cancer: A Review, The Oncologist, vol.17, issue.2, pp.201-212, 2012.
DOI : 10.1634/theoncologist.2011-0300

URL : http://theoncologist.alphamedpress.org/content/17/2/201.full.pdf

M. Saif, Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer, World Journal of Gastroenterology, vol.15, issue.31, pp.3855-64, 2009.
DOI : 10.3748/wjg.15.3855

URL : http://europepmc.org/articles/pmc2731247?pdf=render

M. Ychou, M. Rivoire, and S. Thezenas, A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial, Annals of Surgical Oncology, vol.16, issue.13, pp.4289-97, 2013.
DOI : 10.1634/theoncologist.2011-0141

F. Loupakis, C. Cremolini, and G. Masi, Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.371, issue.17, pp.1609-1627, 2014.
DOI : 10.1056/NEJMoa1403108

C. Cremolini, F. Loupakis, and C. Antoniotti, FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, The Lancet Oncology, vol.16, issue.13, pp.1306-1321, 2015.
DOI : 10.1016/S1470-2045(15)00122-9

A. Falcone, S. Ricci, and I. Brunetti, Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest, Journal of Clinical Oncology, vol.25, issue.13, pp.1670-1676, 2007.
DOI : 10.1200/JCO.2006.09.0928

G. Masi, F. Loupakis, and L. Pollina, Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases, Annals of Surgery, vol.249, issue.3, pp.420-425, 2009.
DOI : 10.1097/SLA.0b013e31819a0486

G. Folprecht, T. Gruenberger, and W. Bechstein, Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial, The Lancet Oncology, vol.11, issue.1, pp.38-47, 2010.
DOI : 10.1016/S1470-2045(09)70330-4

J. Garcia-foncillas and E. Diaz-rubio, Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome, Clinical and Translational Oncology, vol.13, issue.Suppl, pp.533-575, 2010.
DOI : 10.3748/wjg.v13.i44.5867

M. Ducreux, J. Raoul, and P. Marti, High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?, Oncology, vol.25, issue.1-2, pp.17-24, 2008.
DOI : 10.1200/JCO.2007.12.8595

E. Gamelin, R. Delva, and J. Jacob, Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.13, pp.2099-105, 2008.
DOI : 10.1200/JCO.2007.13.3934

J. Saam, G. Critchfield, S. Hamilton, B. Roa, R. Wenstrup et al., Body Surface Area???based Dosing of 5-Fluoruracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens, Clinical Colorectal Cancer, vol.10, issue.3, pp.203-209, 2011.
DOI : 10.1016/j.clcc.2011.03.015

O. Capitain, A. Asevoaia, and M. Boisdron-celle, Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study, Clinical Colorectal Cancer, vol.11, issue.4, pp.263-270, 2012.
DOI : 10.1016/j.clcc.2012.05.004

R. Kaldate, A. Haregewoin, C. Grier, S. Hamilton, and H. Mcleod, Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6, The Oncologist, vol.17, issue.3, pp.296-302, 2012.
DOI : 10.1634/theoncologist.2011-0357

URL : http://theoncologist.alphamedpress.org/content/17/3/296.full.pdf

R. Mathijssen, J. Verweij, M. De-jonge, K. Nooter, G. Stoter et al., Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations, Journal of Clinical Oncology, vol.20, issue.1, pp.81-88, 2002.
DOI : 10.1200/JCO.2002.20.1.81

F. Jong, R. Mathijssen, R. Xie, J. Verweij, and A. Sparreboom, Flat-Fixed Dosing of Irinotecan: Influence on Pharmacokinetic and Pharmacodynamic Variability, Clinical Cancer Research, vol.10, issue.12, pp.4068-71, 2004.
DOI : 10.1158/1078-0432.CCR-03-0591

K. Fujita, Y. Kubota, H. Ishida, and Y. Sasaki, Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer, World Journal of Gastroenterology, vol.21, issue.43, pp.12234-12282, 2015.
DOI : 10.1200/JCO.2006.09.6115

URL : http://doi.org/10.3748/wjg.v21.i43.12234

M. Ducreux, C. Köhne, and G. Schwartz, Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers, Annals of Oncology, vol.14, issue.90002, pp.17-23, 2003.
DOI : 10.1093/annonc/mdg724

URL : https://academic.oup.com/annonc/article-pdf/14/suppl_2/ii17/388346/mdg724.pdf

E. Van-cutsem, S. Tejpar, and D. Vanbeckevoort, Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study, Journal of Clinical Oncology, vol.30, issue.23, pp.2861-2869, 2012.
DOI : 10.1200/JCO.2011.40.9243

D. Abigerges, G. Chabot, J. Armand, P. Herait, A. Gouyette et al., Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients., Journal of Clinical Oncology, vol.13, issue.1, pp.210-231, 1995.
DOI : 10.1200/JCO.1995.13.1.210

Y. Merrouche, J. Extra, and D. Abigerges, High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study., Journal of Clinical Oncology, vol.15, issue.3, pp.1080-1086, 1997.
DOI : 10.1200/JCO.1997.15.3.1080

M. Ychou, J. Raoul, and F. Desseigne, High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer, Cancer Chemother Pharmacol, vol.50, pp.383-91, 2002.

E. Van-cutsem, L. Dirix, V. Laethem, and J. , Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study, British Journal of Cancer, vol.50, issue.Suppl 4, pp.1055-62, 2005.
DOI : 10.1007/s00280-002-0506-7

M. Ducreux, M. Ychou, and J. Seitz, Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.17, issue.9, pp.2901-2909, 1999.
DOI : 10.1200/JCO.1999.17.9.2901

J. Duffour, S. Gourgou, and F. Desseigne, Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer, Cancer Chemotherapy and Pharmacology, vol.50, issue.3, pp.383-392, 2007.
DOI : 10.1007/s00280-006-0372-9

M. Ducreux, J. Raoul, and P. Marti, High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?, Oncology, vol.25, issue.1-2, pp.17-24, 2008.
DOI : 10.1200/JCO.2007.12.8595

E. Rouits, M. Boisdron-celle, and A. Dumont, Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity: A Molecular and Clinical Study of 75 Patients, Clinical Cancer Research, vol.10, issue.15, pp.5151-5160, 2004.
DOI : 10.1158/1078-0432.CCR-03-0548

A. Morel, M. Boisdron-celle, and L. Fey, Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms (SNP) upon 5-fluorouracil tolerance in a prospective clinical study in a French caucasian population, Mol Cancer Ther, vol.11, pp.2895-904, 2006.

E. Rouits, V. Charasson, and A. Pétain, Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients, British Journal of Cancer, vol.18, issue.8, pp.1239-1284, 2008.
DOI : 10.1200/JCO.2005.05.5400

H. Mcleod, D. Sargent, and S. Marsh, Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741, Journal of Clinical Oncology, vol.28, issue.20, pp.3227-3260, 2010.
DOI : 10.1200/JCO.2009.21.7943

O. Capitain, M. Boisdron-celle, and A. Poirier, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer, The Pharmacogenomics Journal, vol.16, issue.4, pp.256-67, 2008.
DOI : 10.1016/j.clinbiochem.2006.07.012

M. Dias, R. Mckinnon, and M. Sorich, allele on response to irinotecan: a systematic review and meta-analysis, Pharmacogenomics, vol.11, issue.8, pp.889-99, 2012.
DOI : 10.1023/A:1026251202137

E. Gamelin, M. Boisdron-celle, and V. Guérin-meyer, Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage, Journal of Clinical Oncology, vol.17, issue.4, pp.1105-1115, 1999.
DOI : 10.1200/JCO.1999.17.4.1105

N. Azzopardi, T. Lecomte, and D. Ternant, Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients, Clinical Cancer Research, vol.17, issue.19, pp.6329-6366, 2011.
DOI : 10.1158/1078-0432.CCR-11-1081

URL : https://hal.archives-ouvertes.fr/hal-00616314

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009.
DOI : 10.1016/j.ejca.2008.10.026

D. Gramont, A. Bosset, J. Milan, and C. , Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study., Journal of Clinical Oncology, vol.15, issue.2, pp.808-823, 1997.
DOI : 10.1200/JCO.1997.15.2.808

E. Van-cutsem, C. Köhne, and E. Hitre, Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009.
DOI : 10.1056/NEJMoa0805019

M. Peeters, T. Price, and A. Cervantes, Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.28, issue.31, pp.4706-4719, 2010.
DOI : 10.1200/JCO.2009.27.6055

C. Bokemeyer, E. Van-cutsem, and P. Rougier, Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials, European Journal of Cancer, vol.48, issue.10
DOI : 10.1016/j.ejca.2012.02.057

, Eur J Cancer, vol.48, issue.10, pp.1466-75, 2012.

M. Hebbar, M. Ychou, and M. Ducreux, Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer, Journal of Cancer Research and Clinical Oncology, vol.50, issue.Suppl 2, pp.749-52, 2009.
DOI : 10.1007/s00432-009-0580-x